An Investigation of Factors Contributing to Higher Levels of Placebo Response in Clinical Trials in Neuropathic Pain: A Systematic Review and Meta-Analysis

Clinical Drug Investigation

Volumn 35, Issue 2, 2015, Pages 67-81

  Arakawa, Akio ^a   Kaneko, Masayuki ^a   Narukawa, Mamoru ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ANALGESIC AGENT;

AGE; CENTRAL NEUROPATHIC PAIN; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; GENDER; HUMAN; META ANALYSIS; NEUROPATHIC PAIN; PAIN INTENSITY; PERIPHERAL NEUROPATHY; PLACEBO EFFECT; POSTHERPETIC NEURALGIA; POSTTRAUMATIC PAIN; POSTTRAUMATIC PERIPHERAL NEUROPATHIC PAIN; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; DOUBLE BLIND PROCEDURE; NEURALGIA;

ANALGESICS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; NEURALGIA; PLACEBOS;

EID: 84925502891     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0259-1     Document Type: Review

References (98)

1. European Medical Agency. Guideline on clinical medical products intended for the treatment of neuropathic pain. 2007. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000425.jsp&mid=WC0b01ac0580034cf5. Accessed 22 Aug 2014.
2. U.S. Food and Drug Administration. Guidance for Industry–Analgesic Indications: Developing Drug and Biological Products [Draft guidance]. February 2014. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 22 Aug 2014.
3. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010;149:177–93.
4. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain. 2010;150:12–6.
5. Cepeda MS, Berlin JA, Gao CY, et al. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis. Pain Med. 2012;13:575–95.
6. Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain. 2008;138:479–83.
7. Irizarry MC, Webb DJ, Ali Z, et al. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009;25:469–76.
8. Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30:664–9.
9. Häuser W, Bartram-Wunn E, Bartram C, et al. Systematic review: Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain. 2011;152:1709–17.
10. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology. 2008;70:263–72.
11. Dworkin DH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524–34.
12. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–21.
13. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–58.
14. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152:2204–5.
15. Stacey BR, Barrett JA, Whalen E, et al. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008;9:1006–17.
16. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009;25:185–92.
17. Pharmaceutical and Medical Devices Agency [in Japanese]. Pregabalin CTD Study 1008-030. http://www.info.pmda.go.jp/shinyaku/P201000025/index.html. Accessed 1 Feb 2014.
18. U.S. Food and Drug Administration. Lyrica NDA #021723 Study 1008-030. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=LYRICA. Accessed 1 Feb 2014.
19. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003;104:323–31.
20. Rice AS, Maton S. Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215–24.
21. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–42.
22. U.S. Food and Drug Administration. Neurontin NDA #021397 Study 945-211. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=NEURONTIN. Accessed 1 Feb 2014.
23. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274–83.
24. U.S. Food and Drug Administration. Lyrica NDA #021446 Study 1008-127. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=LYRICA. Accessed 1 Feb 2014.
25. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35.
26. U.S. Food and Drug Administration. Lyrica NDA #021446 Study 1008-045. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=LYRICA. Accessed 1 Feb 2014.
27. Kochar DK, Garg P, Bumb RA, et al. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. Q J Med. 2005;98:29–34.
28. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Invest. 2010;30:765–76.
29. NCT00612105. Retigabine Study VRX-RET-E22-NP201. http://www.clinicaltrials.gov/ct2/show/study/NCT00612105?term=NCT00612105&rank=1. Accessed 1 Feb 2014.
30. Sang CN, Sathyanarayana R, Sweeney M, et al. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain. 2013;29:281–8.
31. van Seventer R, Feister HA, Young JP Jr, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22:375–84.
32. NCT00394901. Pregabalin Study A0081120. http://www.clinicaltrials.gov/ct2/show/NCT00394901?term=NCT00394901&rank=1. Accessed 1 Feb 2014.
33. Ogawa S, Suzuki M, Arakawa A, et al. Efficacy and tolerability of pregabalin for postherpetic neuralgia: a multicenter, randomized, double-blind, placebo-controlled clinical trial[in Japanese]. Journal of the Japan Society of Pain Clinicians. 2010;17:141–52.
34. Zhang L, Rainka M, Freeman R, et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14:590–603.
35. NCT00592774. Perampanel Study E2007-A001-218. http://www.clinicaltrials.gov/ct2/show/NCT00592774?term=NCT00592774&rank=1. Accessed 1 Feb 2014.
36. Sandercock D, Cramer M, Biton V, et al. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Res Clin Pract. 2012;97:438–45.
37. NCT00857623. AZD2066 Study D0475C00009. http://www.clinicaltrials.gov/ct2/show/NCT00857623?term=NCT00857623&rank=1. Accessed 1 Feb 2014.
38. NCT01201317. AZD2423 Study D2600C00005. http://www.clinicaltrials.gov/ct2/show/NCT01201317?term=NCT01201317&rank=1. Accessed 1 Feb 2014.
39. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–10.
40. U.S. Food and Drug Administration. Lyrica NDA #021446 Study 1008-029. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=LYRICA. Accessed 1 Feb 2014.
41. NCT00785577. LY545694 Study 11977/ H8C-MC-LQBF. http://www.clinicaltrials.gov/ct2/show/NCT00785577?term=NCT00785577&rank=1. Accessed 1 Feb 2014.
42. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697–706.
43. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253–60.
44. Rowbotham MC, Duan WR, Thomas J, et al. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain. 2009;146:245–52.
45. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505–9.
46. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–38.
47. U.S. Food and Drug Administration. Lyrica NDA #021446 study 1008-131. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=LYRICA. Accessed 1 Feb 2014.
48. 2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain. Pain. 2012;153:862–8.
49. Pharmaceutical and Medical Devices Agency [in Japanese]. Pregabalin CTD Study 1008-040. http://www.info.pmda.go.jp/shinyaku/P201000025/index.html. Accessed 1 Feb 2014.
50. Freeman R, Raskin P, Hewitt DJ, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23:147–61.
51. Rauck RL, Shaibani A, Biton V, et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23:150–8.
52. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63:865–73.
53. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–18.
54. Skljarevski V, Frakes EP, Sagman D. Review of efficacy and safety of duloxetine 40 to 60 mg once daily in patients with diabetic peripheral neuropathic pain. Pain Res Treat. 2012;. doi:10.1155/2012/898347.
55. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–56.
56. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. 2005;6:225–34.
57. Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411–20.
58. Tolle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203–13.
59. Gao Y, Ning G, Jia WP, et al. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J. 2010;123:3184–92.
60. Yasuda H, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan. J Diabetes Invest. 2011;2:132–9.
61. Pharmaceutical and Medical Devices Agency [in Japanese]. Pregabalin CTD Study A0081030. http://www.info.pmda.go.jp/shinyaku/P201000025/index.html. Accessed 1 Feb 2014.
62. Arezzo JC, Rosenstock J, LaMoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33–46.
63. Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28:109–16.
64. Shaibani AI, Pope LE, Thisted R, et al. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med. 2012;13:243–54.
65. Rauck R, Makumi CW, Schwartz S, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013;13:485–96.
66. Pharmaceutical and Medical Devices Agency [in Japanese]. Pregabalin CTD Study A0081071. http://www.info.pmda.go.jp/shinyaku/P201000025/index.html. Accessed 1 Feb 2014.
67. NCT00283842. Desvenlafaxine Study 3151A5-322. http://www.clinicaltrials.gov/ct2/show/NCT00283842?term=NCT00283842&rank=1. Accessed 1 Feb 2014.
68. Smith T, DiBernardo A, Shi Y, et al. Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: results from 3 randomized, double-blind placebo-controlled trials. Pain Pract. 2014;14:332–42.
69. NCT00505284. Perampanel Study E2007-G000-227/2006-006488-22. http://www.clinicaltrials.gov/ct2/show/NCT00505284?term=NCT00505284&rank=1. Accessed 1 Feb 2014.
70. Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9:543–54.
71. Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. 2009;10:818–28.
72. Wymer JP, Simpson J, Sen D, et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25:376–85.
73. Ziegler D, Hidvegi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. 2010;33:839–41.
74. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128:169–79.
75. Kalliomaki J, Attal N, Jonzon B, et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain. 2013;154:761–7.
76. Ostenfeld T, Krishen A, Lai RY, et al. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study. Eur J Pain. 2013;17:844–57.
77. van Seventer R, Bach FW, Toth CC, et al. Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol. 2010;17:1082–9.
78. Simpson DM, Schifitto G, Clifford DB, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010;74:413–20.
79. NCT00109772. Lenalidomide Study CC-5013-CRPS-002. http://www.clinicaltrials.gov/ct2/show/NCT00109772?term=NCT00109772&rank=1. Accessed 1 Feb 2014.
80. Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial. Pain. 2003;103:277–83.
81. Moon DE, Lee DI, Lee SC, et al. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010;32:2370–85.
82. Guan Y, Ding X, Cheng Y, et al. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. Clin Ther. 2011;33:159–66.
83. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254–63.
84. NCT01124617. Tapentadol Study CR017002/JNS024ER-JPN-N22. http://www.clinicaltrials.gov/ct2/show/NCT01124617?term=NCT01124617&rank=1. Accessed 1 Feb 2014.
85. Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006;67:1792–800.
86. U.S. Food and Drug Administration. Lyrica NDA #021446 Study 1008-125. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=LYRICA. Accessed 1 Feb 2014.
87. Cardenas DD, Nieshoff EC, Suda K, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013;80:533–9.
88. Kim JS, Bashford G, Murphy TK, et al. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain. 2011;152:1018–23.
89. Vollmer TL, Robinson MJ, Risser RC, et al. A randomised, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patient with multiple sclerosis. Pain Practice. 2013; doi:10.1111/papr.12127
90. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150–7.
91. Serpell MG. Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557–66.
92. Kost RG, Straus SE. Postherpetic neuralgia – pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32–42.
93. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565–90.
94. Linde K, Witt CM, Streng A, et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain. 2007;128:264–71.
95. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology. 2005;65:S32–49.
96. Dworkin RH, Katz J, Gitlin MJ, et al. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology. 2005;65:S7–19.
97. Sakai F, Diener HC, Ryan R, et al. Eletriptan for the acute treatment of migraine: results of bridging a Japanese study to Western clinical trials. Curr Med Res Opin. 2004;20:269–77.
98. Wang SJ, Fuh JL, Wu ZA. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc. 2007;70:39–46.